Patent Law Weblog
Category: Licensing
-
By Sherri Oslick — GlaxoSmithKline of London, UK and Philadelphia, PA and Reliant Pharmaceuticals of Liberty Corner, NJ have announced an agreement under which GSK will acquire Reliant for $1.65 billion in cash. Reliant is a privately held pharmaceutical company focused on cardiovascular therapeutics. Reliant’s therapeutic portfolio has been developed through in-licensing and…
-
By Christopher P. Singer — In a November 16, 2007 press release, Pfizer Inc. announced that it will acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY). Coley is a biopharmaceutical company that has several research programs which include vaccine adjuvants (VaxImmune®) as well as a class of immunomodulatory drug candidates that are designed to…
-
By Sherri Oslick — Genzyme Corporation of Cambridge, MA has announced that Bioenvision, Inc. (New York, NY) stockholders approved the acquisition of the company by Genzyme for roughly $345 million in cash. The acquisition suffered from a number of bumps in the road, starting with disapproval of the deal by a key stockholder…
-
By Donald Zuhn — On Monday, SparkIP launched a beta version of its new online intellectual property exchange, SparkIP.com. The site, which SparkIP describes as "an advanced research and commerce platform for the scientific community," is designed to connect scientists, inventors, licensors, licensees, corporations, universities, government labs, and patent attorneys with one another;…
-
By Jason Derry — Anacor Pharmaceuticals and GlaxoSmithKline have announced an agreement relative to discovery, development, and commercialization of therapeutics for viral and bacterial diseases. Anacor develops small molecule therapeutics based on a boron chemistry platform. The agreement provides GlaxoSmithKline the option to select up to four targets for drug candidate development, with…
-
By Jason Derry — Alethia Biotherapeutics Inc. has announced a licensing agreement with the National Research Council Biotechnology Research Institute (NRC-BRI). Under the terms of the agreement, Alethia receives exclusive worldwide rights to a family of monoclonal antibodies that specifically block activity of secreted clusterin. Alethia plans to move the anti-clusterin antibodies, which…
-
By Sherri Oslick — Last week, Bristol-Myers Squibb Co. of Princeton, NJ announced that it would acquire biotechnology company Adnexus Therapeutics Inc. of Waltham, MA for $430 million in cash (with an additional $75 million to be paid provided Adnexus meets certain regulatory milestones). Adnexus is a privately held company developing a proprietary…
-
By Jason Derry — Array BioPharma Inc. and Celgene Corp. have announced an agreement to collaborate in discovery, development, and commercialization of therapeutics for cancer and inflammation. Under the terms of the agreement, Celgene will pay Array BioPharma $40 million at the outset of the collaboration. Array and Celgene will mutually select four…
-
By Jason Derry — Exelixis and Bristol-Myers Squibb have announced an agreement to extend their research collaboration relating to cardiovascular and metabolic diseases for an additional year, now ending in January 2009. Under the terms of the extension, Exelixis will receive an additional $7.5 million in funding. The collaboration is focused on developing…
-
By Sherri Oslick — On Thursday, Celera of Rockville, MD and Alameda, CA, an Applera Corporation business, announced that it would acquire Atria Genetics, Inc. of San Fransisco, CA for approximately $33 million cash. Atria Genetics is a private company that has developed a line of human leukocyte antigen (HLA) testing products that…
Patent Docs 